

CVD escalation therapy for secondary prevention (update) committee meeting 2

Date: 9/3/2023

Location: Virtual via Zoom

Minutes: Final

Committee members present:	
Beverley Bostock	
Hugh Gallagher	
Satwinder Kaur	Present for items 3-6
Joseph Mills (Chair)	
Riyaz Patel (Topic adviser)	
David Preiss	
Ruth Price	Present for items 3-6
Chakravarthi Rajkumar (Co-opted member)	Present for items 1-3
Eduard Shantsila	
Wayne Sunman	
Colin Wilkinson	Present for items 1-4

In attendance:		
Serena Carville	Associate Director/Guideline Lead	
Catrina Charlton	Guideline Commissioning Manager	
Alfredo Mariani	Technical Analyst (Economics)	
Joanna Perkin	Medical Editor	
Eleanor Samarasekera	Senior Systematic Reviewer	
Amelia Unsworth	Senior Project Manager	
Melina Vasileiou	Technical Analyst	
David Wonderling	Head of Health Economics	

4.0.03 DOC Cmte minutes

Observers:	
None	

Apologies:	
Nigel Beckett	Committee member
Chris Clark	Committee member
Parijat De	Co-opted member
Aroon Hingorani	Co-opted member
Paul Leeson	Committee member
Lina Gulhane	Head of Information Specialists, GDT NGC
Miaoqing Yang	Technical Analyst (Economics)

1. Welcome and objectives for the meeting				
<p>The Chair welcomed the Committee members and attendees to the 2nd meeting on CVD escalation therapy for secondary prevention.</p> <p>The Chair gave a tribute to MG who sadly passed away recently and noted that there would be acknowledgement of MG's contribution to the CVD prevention guideline updates.</p> <p>The Chair informed the Committee that apologies had been received. These are noted above.</p> <p>The Chair outlined the objectives of the meeting, which included: review of the clinical evidence for lipid-lowering therapies for people with CVD requiring escalation of therapy for secondary prevention, and discussion of the plans for the economic model.</p>				
2. Confirmation of matters under discussion, and declarations of interest				
<p>The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were:</p> <ul style="list-style-type: none"> lipid-lowering therapies for escalation of therapy for secondary prevention for people with CVD. <p>The Chair asked everyone to verbally declare any interests in addition to those previously declared.</p>				
Name	Job title,	Declarations of	Type of	Decision

4.0.03 DOC Cmte minutes

	organisation	Interest, date declared	interest	taken
Ruth Price	Advanced Clinical Pharmacist for Cardiovascular Services, Leeds Teaching Hospitals NHS Trust	As a member of the UKCPA (UK Clinical Pharmacy Association) Cardiac committee, I provided feedback to the AHSN for a lipid optimisation secondary prevention of cardiovascular disease pathway. The UKCPA committee have endorsed this pathway (not yet published), 21.2.23.	Direct non-financial professional and personal	Specific Declare and remain Directly relevant, however the work does not pose a conflict to the topics under consideration in the guideline as the response was a contribution to the UKCPA overall response, within which the committee member does not hold a position of office. Furthermore, this update will not develop a pathway of lipid treatment options
Ruth Price	Advanced Clinical Pharmacist for Cardiovascular Services, Leeds Teaching Hospitals NHS Trust	Attended an AstraZeneca sponsored meal on 7 February 2023 educational event - presentations and a panel discussion "Simplifying the management of heart failure across a range of ejection fractions".	Direct financial	Non-specific Reasonable subsistence No action needed other than process of open declaration

4.0.03 DOC Cmte minutes

RPr declared that she provided feedback to the AHSN for a lipid optimisation secondary prevention of cardiovascular disease pathway in her capacity as a UK Clinical Pharmacy Association Cardiac committee member. And RPr had attended an AstraZeneca sponsored meal on 7 February 2023 educational event - presentations and a panel discussion “Simplifying the management of heart failure across a range of ejection fractions”.

The Chair and a senior member of the Developer’s team did not consider that these activities posed a conflict with the matters under discussion, therefore no further action was required.

The Chair and a senior member of the Developer’s team reviewed the declarations of interest register for interests previously declared and noted that none posed a conflict with the matters under discussion, therefore no further action was required.

3. Evidence review: Escalation of therapy for secondary prevention

The Committee was given a presentation on the clinical evidence for lipid-lowering therapies for escalation of treatment for secondary prevention, and the results of the network meta-analysis.

4. Health economic model

The Committee was given a presentation on the plans for the economic model.

5. Minutes of the previous meeting

The minutes of the previous meeting were agreed as an accurate record.

6. Any other business

None

Date of next meeting: 30/3/23

Location of next meeting: Virtual via Zoom